JP5528436B2 - 抗炎症剤 - Google Patents

抗炎症剤 Download PDF

Info

Publication number
JP5528436B2
JP5528436B2 JP2011512123A JP2011512123A JP5528436B2 JP 5528436 B2 JP5528436 B2 JP 5528436B2 JP 2011512123 A JP2011512123 A JP 2011512123A JP 2011512123 A JP2011512123 A JP 2011512123A JP 5528436 B2 JP5528436 B2 JP 5528436B2
Authority
JP
Japan
Prior art keywords
antibody
seq
antibodies
human
citrulline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011512123A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011523555A (ja
Inventor
マリア ヘンドリック ラーツ，ヨーゼフ
ヘラルデュス シルファーノ シーリフィ，レナート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Modiquest BV
Original Assignee
Modiquest BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modiquest BV filed Critical Modiquest BV
Publication of JP2011523555A publication Critical patent/JP2011523555A/ja
Application granted granted Critical
Publication of JP5528436B2 publication Critical patent/JP5528436B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
JP2011512123A 2008-06-04 2009-06-04 抗炎症剤 Active JP5528436B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP08157547.4 2008-06-04
EP08157547 2008-06-04
EP08171920.5 2008-12-17
EP08171920 2008-12-17
EP09155484 2009-03-18
EP09155484.0 2009-03-18
PCT/EP2009/056862 WO2009147201A2 (en) 2008-06-04 2009-06-04 Anti-inflammatory agents

Publications (2)

Publication Number Publication Date
JP2011523555A JP2011523555A (ja) 2011-08-18
JP5528436B2 true JP5528436B2 (ja) 2014-06-25

Family

ID=40943595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011512123A Active JP5528436B2 (ja) 2008-06-04 2009-06-04 抗炎症剤

Country Status (16)

Country Link
US (2) US9718877B2 (https=)
EP (1) EP2294086B1 (https=)
JP (1) JP5528436B2 (https=)
KR (1) KR101752499B1 (https=)
CN (1) CN102056944A (https=)
AU (1) AU2009253923B2 (https=)
BR (1) BRPI0913945A2 (https=)
CA (1) CA2726511C (https=)
DK (1) DK2294086T3 (https=)
EA (1) EA023302B9 (https=)
ES (1) ES2652127T3 (https=)
IL (1) IL209741A0 (https=)
NO (1) NO2294086T3 (https=)
PL (1) PL2294086T3 (https=)
WO (1) WO2009147201A2 (https=)
ZA (1) ZA201008727B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2294086T3 (https=) 2008-06-04 2018-02-10
EP2332987A1 (en) 2009-12-10 2011-06-15 ModiQuest B.V. Anti-inflammatory agents directed against citrullinated epitopes
US20110262505A1 (en) 2010-04-22 2011-10-27 Gina Athwal Seaweed-derived cosmetic compositions
EP2402368A1 (en) 2010-07-02 2012-01-04 Toscana Biomarkers S.r.l. Histone citrullinated peptides and uses thereof
EP2527841A1 (en) * 2011-05-25 2012-11-28 Toscana Biomarkers S.r.l. Methods for the diagnosis of rheumatoid arthritis
WO2013105721A1 (ko) * 2012-01-13 2013-07-18 가톨릭대학교 산학협력단 류마티스 관절염 진단 키트
US9347941B2 (en) 2012-01-13 2016-05-24 Catholic University Industry-Academic Cooperation Foundation Diagnosis kit for rheumatoid arthritis
WO2013109185A1 (en) * 2012-01-19 2013-07-25 Vilara Ab Novel antibodies
FR3007411B1 (fr) * 2013-06-21 2015-07-03 Agronomique Inst Nat Rech Anticorps monocatenaire a chaine lourde de camelide dirige contre la chromatine et utilisations
US20160159922A1 (en) * 2013-07-24 2016-06-09 Vilara Ab Novel Antibodies for the Diagnosis and Treatment of Rheumatoid Arthritis
CA2946925C (en) * 2014-05-05 2023-08-15 Noviosmart Method for the serological diagnosis of rheumatoid arthritis.
JP7037940B2 (ja) 2014-12-11 2022-03-17 シトリル べー．フェー． 特発性肺線維症の治療方法
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
CA2984380A1 (en) * 2015-05-05 2016-11-10 The Regents Of The University Of California H3.3 ctl peptides and uses thereof
EP3713966A1 (en) 2017-11-22 2020-09-30 Vacara AB Antibodies to citrullinated proteins
CU24508B1 (es) * 2017-12-29 2021-04-07 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica que comprende péptido tipo apl
CA3102360A1 (en) * 2018-06-20 2019-12-26 Pharma Foods International Co., Ltd. Novel anti-pad2 antibody
EP3841120B1 (en) * 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4
KR20240005856A (ko) 2021-05-04 2024-01-12 씨트릴 비.브이. 세포 외 트랩 억제
EP4085973A1 (en) 2021-05-04 2022-11-09 Citryll B.V. Inhibition of eosinophil extracellular traps
EP4442705A1 (en) 2023-04-03 2024-10-09 Citryll B.V. Dosage
GB202318703D0 (en) 2023-12-07 2024-01-24 Citryll B V Diagnostic agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
NL1004539C2 (nl) 1996-11-15 1998-05-20 Stichting Tech Wetenschapp Peptide afgeleid van een door auto-antilichamen van patiënten met reumatoïde artritis herkend antigeen, antilichaam daartegen en werkwijze voor het detecteren van auto-immuunantilichamen.
EP1034186A2 (en) * 1997-11-28 2000-09-13 Innogenetics N.V. Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
CA2391356A1 (en) 1999-12-21 2001-06-28 Innogenetics N.V. Peptides designed for the diagnosis and treatment of rheumatoid arthritis
JP2007524583A (ja) 2003-03-07 2007-08-30 ロンドン・ヘルス・サイエンシズ・センター・リサーチ・インコーポレーテッド 自己免疫異常に関わるｈｌａ−ｄｒｍｈｃクラスｉｉ分子に関するペプチド
GB0721605D0 (en) 2007-11-02 2007-12-12 Cancer Rec Tech Ltd Prostrate cancer susceptibility screening
NO2294086T3 (https=) 2008-06-04 2018-02-10

Also Published As

Publication number Publication date
ZA201008727B (en) 2012-01-25
US9718877B2 (en) 2017-08-01
AU2009253923A1 (en) 2009-12-10
CN102056944A (zh) 2011-05-11
CA2726511C (en) 2018-07-10
BRPI0913945A2 (pt) 2016-09-27
EP2294086A2 (en) 2011-03-16
EA023302B1 (ru) 2016-05-31
PL2294086T3 (pl) 2018-02-28
CA2726511A1 (en) 2009-12-10
NO2294086T3 (https=) 2018-02-10
EA023302B9 (ru) 2016-10-31
EP2294086B1 (en) 2017-09-13
ES2652127T3 (es) 2018-01-31
WO2009147201A3 (en) 2010-01-28
US10703822B2 (en) 2020-07-07
KR101752499B1 (ko) 2017-06-29
US20110243945A1 (en) 2011-10-06
JP2011523555A (ja) 2011-08-18
KR20110015035A (ko) 2011-02-14
DK2294086T3 (en) 2018-01-02
AU2009253923B2 (en) 2014-02-13
IL209741A0 (en) 2011-02-28
EA201001865A1 (ru) 2011-06-30
WO2009147201A2 (en) 2009-12-10
US20170298146A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
JP5528436B2 (ja) 抗炎症剤
JP5980683B2 (ja) シトルリン化エピトープに対する抗炎症剤
JP7835788B2 (ja) シトルリン化されたヒストン２ａ及び／又は４に結合する抗体
Chirivi et al. Anti-citrullinated protein antibodies as novel therapeutic drugs in rheumatoid arthritis
JP2024508611A (ja) 方法
HK1156050A (en) Anti-inflammatory agents
EP4260872A1 (en) Agent for preventing or treating frontotemporal lobar degeneration
WO2024235910A1 (en) Nanobody for treating inflammation, autoinflammation or cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140415

R150 Certificate of patent or registration of utility model

Ref document number: 5528436

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250